<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ayu</journal-id><journal-id journal-id-type="iso-abbrev">Ayu</journal-id><journal-id journal-id-type="publisher-id">AYU</journal-id><journal-title-group><journal-title>Ayu</journal-title></journal-title-group><issn pub-type="ppub">0974-8520</issn><issn pub-type="epub">0976-9382</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25558160</article-id><article-id pub-id-type="pmc">4279321</article-id><article-id pub-id-type="publisher-id">AYU-35-152</article-id><article-id pub-id-type="doi">10.4103/0974-8520.146231</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>A comparative clinical study of <italic>Asanadi Ghanavati</italic> and <italic>Gomutra Haritaki</italic> in <italic>Kapha Medo Margavarana</italic> (dyslipidemia)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Joshi</surname><given-names>Shivam G.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Chandola</surname><given-names>Hari Mohan</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Dave</surname><given-names>Alankruta R.</given-names></name><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1">Department of Kaya Chikitsa, Institute for Post-Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India</aff><aff id="aff2"><label>1</label>Ch. Brahm Prakash Charak Ayurved Sansthana, Khera Dabar, New Delhi, India</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Shivam G. Joshi, Ph.D. Scholar, Department of Kaya Chikitsa, I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar - 361 008, Gujarat, India. E-mail: <email xlink:href="ayuholistichealth@gmail.com">ayuholistichealth@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Apr-Jun</season><year>2014</year></pub-date><volume>35</volume><issue>2</issue><fpage>152</fpage><lpage>159</lpage><permissions><copyright-statement>Copyright: &#x000a9; AYU (An International Quarterly Journal of Research in Ayurveda)</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>Dyslipidemia is a disorder of lipoprotein metabolism, including lipoprotein overproduction or deficiency and it can be understood in the parlance of the closest conditions in Ayurveda, viz. <italic>Kapha Medo Margavarana</italic> (dyslipidemia), <italic>Atisthaulya</italic> (obesity) or <italic>Meda Roga</italic> and <italic>Prameha</italic>. <italic>Asanadi Ghanavati</italic> (AG) is a modified presentation of <italic>Asanadi Gana</italic> drugs referred in <italic>Ashtanga Hridaya</italic> and <italic>Gomutra Haritaki</italic> (GH) is described in <italic>Charaka Samhita</italic> under <italic>Shotha Chikitsa</italic> and Ashtanga Hridaya in <italic>Arsha Chikitsa</italic>.</p></sec><sec id="st2"><title>Aim:</title><p>To evaluate and compare the clinical effect of AG and GH in <italic>Kapha Medo Margavarana</italic>.</p></sec><sec id="st3"><title>Materials and Methods:</title><p>Patients with the high lipid profile were selected and randomly divided into two groups. In Group A (<italic>n</italic> = 30), patients were administered with tablet of AG 1 g (500 mg each) thrice a day for 8 weeks and in Group B (<italic>n</italic> = 30), tablet of GH in similar dose and duration. Effect of therapy was assessed by body circumference, Body Mass Index (BMI), cardinal symptoms like <italic>Anga-Gaurava</italic>, <italic>Bharavriddhi</italic>, etc., and lipid profile parameters.</p></sec><sec id="st4"><title>Result:</title><p>AG decreased the serum cholesterol by 7.12%, Serum Triglyceride (S. TG) by 7.72%, Serum Low Density Lipoprotein (S. LDL) by 11.68%, Serum Very Low Density Lipoprotein (S. VLDL) by 7.73%, and had increased Serum High Density Lipoprotein (S. HDL) by 9.52%, with moderate improvement in 14.81% and mild improvement in 70.37% of patients. The GH decreased the serum cholesterol by 6.31%, S. TG by 9.61%, S. LDL by 12.55%, serum VLDL by 8.99%, and increased S. HDL by 10.52% with moderate improvement in 3.70%, and mild improvement in 74.07% patients.</p></sec><sec id="st5"><title>Conclusion:</title><p>AG and GH are suggested to be used in <italic>Kleda Bahul Samprapti Janya Vyadhi</italic> and <italic>Ama Bahul Samprapti Janya Vyadhi</italic> respectively.</p></sec></abstract><kwd-group><kwd><italic>Asanadi Ghanavati</italic></kwd><kwd>dyslipidemia</kwd><kwd><italic>Gomutra Haritaki</italic></kwd><kwd><italic>Kapha Medo Margavarana</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>Introduction</title><p>In the modern era, sedentary life-style and drastic changes in food pattern may lead to diseases such as dyslipidemia, type-II Diabetes Mellitus (DM), hypertension, and obesity, which are closely linked with each other and often co-exist in individual making the syndrome more complex and difficult to manage. Dyslipidemia stands as the most firmly established and the modifiable risk factor for cardio- and cerebro-vascular accidents, due to the presence of abnormal level of cholesterol, which is a causative factor for atherosclerosis. According to National Commission on Macroeconomics and Health, there would be around 62 million patients with the Coronary Artery Disease (CAD) by 2015 in India and of these 23 million would be patients younger than 40 years of age.[<xref rid="ref1" ref-type="bibr">1</xref>] The four leading causes of death globally in 2030 are projected to be ischemic heart disease, cerebro-vascular disease (stroke), HIV/AIDS, and chronic obstructive pulmonary disease.[<xref rid="ref2" ref-type="bibr">2</xref>] CAD is usually due to atherosclerosis of large and medium sized arteries, and dyslipidemia has been found to be one of the most significant contributing factors. In Ayurveda, various attempts have been made to use distinctive nomenclature to denote the word dyslipidemia, viz. <italic>Rasagata Sneha Vriddhi</italic>, <italic>Rasa Raktagata Sneha Vriddhi</italic>, <italic>Medodosha</italic>, and <italic>Kapha Medo Margavarana</italic>.</p><p>Dyslipidemia can be taken as <italic>Kapha Medo Margavarana</italic>, which denotes <italic>Samprapti</italic> (pathologenesis) rather than a clinical diagnosis. <italic>Asanadi Ghanavati</italic> (AG) [<xref ref-type="table" rid="T1">Table 1</xref>] is a specific herbal formulation explained in <italic>Shodhanadi Gana Samgraha</italic>.&#x0201d;[<xref rid="ref3" ref-type="bibr">3</xref>] The drugs are indicated specially in the diseases in which <italic>Kapha Dosha</italic> and <italic>Medo Dushya</italic> are vitiated predominantly viz. <italic>Shwitra</italic>, <italic>Kushtha</italic>, <italic>Pandu</italic>, <italic>Prameha</italic>, <italic>Medoroga</italic>, etc., Most of the drugs have <italic>Ruksha</italic> (dry) <italic>Guna</italic> (property), <italic>Kashaya Rasa</italic> (astringent taste), <italic>Katu Vipaka</italic>, <italic>Lekhana</italic> as well as <italic>Chhedana Karma</italic> and are useful in <italic>Kapha Medo Margavarana Janya</italic> condition like dyslipidemia. <italic>Gomutra Haritaki</italic> (GH) is referred for <italic>Kaphaja Shotha Chikitsa</italic>.[<xref rid="ref4" ref-type="bibr">4</xref>] <italic>Haritaki</italic> (<italic>Terminalia chebula</italic> Retz.) and <italic>Gomutra</italic> (cow urine) are the constituents of this formulation. AG and GH can be helpful to destruction the etiopathogenesis of the disease.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Ingredients of <italic>Asanadi Ghanavati</italic></p></caption><graphic xlink:href="AYU-35-152-g001"/></table-wrap><p>So this study was undertaken to evaluate and compare the clinical effect of AG and GH in patients suffering with the <italic>Kapha Medo Margavarana</italic> (dyslipidemia).</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>Materials and Methods</title><sec id="sec2-1"><title>Study design</title><p>It was a randomized, parallel, and interventional clinical trial. Informed consent was taken from all the patients. Patients (<italic>n</italic> = 60) with the high lipid profile were selected during October 2011 to April 2012 from Outdoor Patient Department of Kaya Chikitsa, IPGT and RA, Jamnagar and were alternatively divided into two groups (Group A and B). The research protocol was approved by Institutional Ethics Committee (No. PGT/7-A/Ethics/2011-12/2087; dt. 05-09-2011) and registered in CTRI (No.: CTRI/2011/12/002281).</p></sec><sec id="sec2-2"><title>Inclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Patients with age 25 to 60 years</p></list-item><list-item><p>Elevated levels of serum cholesterol (201 mg/dl or more) and/or elevated serum triglycerides (S. TGs) (151 mg/dl or more) and/or, elevated serum low density lipoprotein (S. LDL) (131 mg/dl or more) and/or elevated serum very low density lipoprotein (S. VLDL) (41 mg/dl or more).[<xref rid="ref5" ref-type="bibr">5</xref>]</p></list-item></list>
</p></sec><sec id="sec2-3"><title>Exclusion criteria</title><p>
<list list-type="bullet"><list-item><p>Patients suffering from type -I DM</p></list-item><list-item><p>Drug induced dyslipidemia</p></list-item><list-item><p>Patients with the serious systemic illness such as tuberculosis, carcinoma, and advanced stage of DM.</p></list-item></list>
</p></sec><sec id="sec2-4"><title>Investigation</title><p>Routine hematological examinations were carried out before and after treatment to rule out any pathological conditions. Bio-chemical test such as complete lipid profile, fasting blood sugar (FBS), serum creatinine, and the blood urea were carried out. Apo-lipoprotein B (Apo-B) as Bio-marker was investigated in 10 patients in each group.</p></sec><sec id="sec2-5"><title>Drugs and posology</title><sec id="sec3-1"><title>Group A</title><p>Tablet of AG (500 mg each) was administered in dose of 2 tablets (1 g), thrice a day with <italic>Ushnodaka</italic> (luke warm water) before food for 8 weeks.</p></sec><sec id="sec3-2"><title>Gorup B</title><p>Tablet of GH was administered in the same dose and duration of group A.</p></sec></sec><sec id="sec2-6"><title>Follow-up</title><p>Follow-up was carried out for 2 weeks after the completion of treatment to see the long-standing effect of the drug.</p></sec><sec id="sec2-7"><title>Pathya-Apathya</title><p>No specific diet or exercise pattern was advised during the study period. Subjects were only advised to avoid the excess usage of oils in the dietary articles.</p></sec><sec id="sec2-8"><title>Criteria for assessment of the total effect of therapy</title><p>The overall effect was assessed on the basis of relief in chief complaints (as subjective criteria) and lipid profile (objective criteria) such as decrease in the serum cholesterol, S. TG, S. LDL, S. VLDL and increase in serum high density lipoprotein (S. HDL).</p><p>The overall effect was assessed on following criteria:</p><p>
<list list-type="bullet"><list-item><p>Complete remission &#x02013; 100% relief</p></list-item><list-item><p>Markedly improved &#x02013; &#x0003c;100% to &#x0003e; 75% relief</p></list-item><list-item><p>Moderately improved &#x02013; 75% to &#x0003e; 50% relief</p></list-item><list-item><p>Mild improvement &#x02013; 50% to &#x0003e; 25% relief</p></list-item><list-item><p>Unchanged &#x02013; 25-0% relief.</p></list-item></list>
</p></sec><sec id="sec2-9"><title>Statistical analysis</title><p>The Wilcoxon signed rank test method was used to check the significance of the subjective criteria and paired <italic>t</italic> test was used for objective criteria in a single group. To compare the effect of therapy of two groups, Chi-square test was carried out for the subjective criteria and unpaired <italic>t</italic> test for objective criteria. The obtained results were interpreted as, insignificant <italic>P</italic> &#x0003e; 0.05, significant <italic>P</italic> &#x0003c; 0.01, highly significant <italic>P</italic> &#x0003c; 0.001</p></sec></sec><sec id="sec1-3"><title>Observations</title><p>Out of 60 patients, the maximum (37%) belonged to age between 45 to 55 years. 50% and 60% patients were male in group A and B respectively. The majority of patients in group A (80%) and group B (70%) were Hindu. 96% of patients of group A and 83.33% of the patients in group B were married. It was observed that, 50% of the females in group A and 40% in group B were housewives in this study. Most of the patients in both groups belonged to middle and rich socio-economic status. In <italic>Nidanas</italic>, <italic>Ahara</italic> was found to be dominant in <italic>Madhura Rasa</italic> (91.33%), <italic>Snigdha Guna</italic> (70%), <italic>Guru Guna</italic> (65%), and <italic>Sheeta Veerya</italic> (63%). <italic>Vishamashana</italic> (68.33%) and <italic>Adhyashana</italic> (36.67%) were found most inappropriate. Maximum patients (90%) were habituated of regular consumption of oily, fried foods, bakery items, curd, etc. In <italic>Vihara</italic>, <italic>Divaswapa</italic> (85%), and <italic>Avyayama</italic> (68.33%) were found most common. In this study, 60% patients had reported of having affection with <italic>Ati-chinta</italic> (stress) and <italic>Krodha</italic> (anger). Most of the patients (71.67%) had gradual onset of disease and the disease was chronic for 1-5 years in 58.33% patients. DM-II and hypertension were observed in 16.67% and 15% patients of both groups. A total of 33.33% patients had a positive family history of dyslipidemia. The majority of patients showed symptoms of <italic>Angagaurava</italic> (76.67%), <italic>Bharavriddhi</italic> (71%), and <italic>Ayase-Shwasa</italic> (53.33%). <italic>Dushti</italic> of <italic>Kapha Dosha</italic>, <italic>Rasa Dhatu</italic>, <italic>Rakta Dhatu</italic>, and <italic>Medo Dhatu</italic> were observed in 78.33%, 88.33%, 30%, and 86.67% respectively. <italic>Dashavidha Pariksha</italic> revealed that 52% of the patients had <italic>Kaphapradhana Pittanubandhi Sharira Prakriti</italic> 67% had <italic>Tamasika Prakriti</italic> 90% were of <italic>Madhyama Sara</italic>, 70% were of <italic>Madhyama Satva</italic>, and 61.67% were of <italic>Madhyama Samhanana</italic>. The study revealed that, 81.67% of the patients had BMI greater than 25 and 70% had body weight between 70 kg and 100 kg.</p></sec><sec sec-type="results" id="sec1-4"><title>Results</title><sec id="sec2-10"><title>Effect of therapy on symptoms</title><p>In group A, there were relief of symptoms <italic>Angagaurava</italic> (85.37%), <italic>Ayase Swasa</italic> (92.91%), <italic>Bharavriddhi</italic> (6.02%), <italic>Atipipasa</italic> (50%), <italic>Atikshudha</italic> (66.65%), <italic>Daurbalya</italic> (81.81%), <italic>Sandhishool</italic> (57%), <italic>Alasya</italic> (55.09%), and <italic>Sphik-Stana-Udara Avalambana</italic> (47.40%). The relief in <italic>Angagaurava</italic>, <italic>Ayase Swasa</italic>, <italic>Alasya</italic>, <italic>Daurbalya</italic>, <italic>Sphik-Stana-Udara Avalambana</italic> was statistically highly significant (<italic>P</italic> &#x0003c; 0.001). Change of relief on <italic>Sandhishoola</italic> was statistically significant (<italic>P</italic> &#x0003c; 0.01). Statistically insignificant results were found in <italic>Atikshudha</italic>, <italic>Atipipasa</italic> and <italic>Bharavridhhi</italic> (<italic>P</italic> &#x0003e; 0.05) [Figures <xref ref-type="fig" rid="F1">1</xref>,<xref ref-type="fig" rid="F2">2</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Effect on subjective criteria</p></caption><graphic xlink:href="AYU-35-152-g002"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Effect on body mass index</p></caption><graphic xlink:href="AYU-35-152-g003"/></fig><p>In group B, relief of symptoms was observed in <italic>Angagaurava</italic> (90.08%), <italic>Ayase Swasa</italic> (87.97%), <italic>Bharavriddhi</italic> (7.05%), <italic>Atipipasa</italic> (75%), <italic>Atikshudha</italic> (73.33%), <italic>Daurbalya</italic> (66.67%), <italic>Sandhishool</italic> (73%), <italic>Alasya</italic> (49.70%), and <italic>Sphik-Stana-Udara Avalambana</italic> (35.61%). The relief in <italic>Angagaurava</italic>, <italic>Ayase Swasa</italic>, <italic>Atipipasa</italic>, <italic>Sandhishool</italic>, and <italic>Sphik-Stana-Udara Avalambana</italic> were statistically highly significant (<italic>P</italic> &#x0003c; 0.001). In <italic>Bharavridhhi</italic>, the relief was statistically significant (<italic>P</italic> &#x0003c; 0.01). Statistically insignificant results were found in <italic>Daurbalya</italic>, <italic>Alasya</italic> and <italic>Atikshudha</italic> (<italic>P</italic> &#x0003e; 0.05) [<xref ref-type="fig" rid="F1">Figure 1</xref>].</p></sec><sec id="sec2-11"><title>Effect on body weight</title><p>Body weight was reduced by 2.53% of the subjects in group A, whereas BMI was reduced by 2.59%. In group B, body weight and BMI were reduced by 3.57% and 2.71% respectively. The changes were statistically highly significant (<italic>P</italic> &#x0003c; 0.001) in both the groups [<xref ref-type="fig" rid="F2">Figure 2</xref>].</p></sec><sec id="sec2-12"><title>Effect on body circumference</title><p>In group A, circumference of chest, abdomen, hip, pelvis, mid-thigh, and calf were reduced by 0.79%, 1.69%, 1.66%, 0.93%, 2.47%, and 1.09% respectively. In group B, circumference of chest, abdomen, hip, pelvis, mid-thigh, and calf were reduced by 0.45%, 1.12%, 1.80%, 0.93%, 2.34%, and 1.76% respectively. The results were found statistically highly significant (<italic>P</italic> &#x0003c; 0.001) in both the groups [<xref ref-type="fig" rid="F3">Figure 3</xref>].</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Effect on body circumference</p></caption><graphic xlink:href="AYU-35-152-g004"/></fig></sec><sec id="sec2-13"><title>Effect on skin folds thickness</title><p>In group A, skin fold thickness of biceps, triceps, and abdomen was reduced by 5.53%, 5.22%, and 4.64% respectively. In group B, skin fold thickness of biceps, triceps, and abdomen was reduced by 4.99%, 4.84%, and 5.05% respectively. The results were found statistically highly significant (<italic>P</italic> &#x0003c; 0.001) in both the groups [<xref ref-type="fig" rid="F4">Figure 4</xref>].</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Effect on skin fold thickness</p></caption><graphic xlink:href="AYU-35-152-g005"/></fig></sec><sec id="sec2-14"><title>Effect on lipid profile</title><p>On statistical evaluation S. cholesterol, S. TGs, S. LDL and S. VLDL were reduced by 7.12%, 7.72%, 11.68%, and 7.73% respectively, whereas S. HDL and apo-lipoprotein were increased by 9.52% and 11.78% respectively in group A. The results were statistically significant in S. cholesterol, S. LDL, S. HDL (<italic>P</italic> &#x0003c; 0.01) and insignificant in S. TG, S. VLDL and apo-lipoprotein (<italic>P</italic> &#x0003e; 0.05) [<xref ref-type="table" rid="T2">Table 2</xref>].</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Effect of therapy on objective criteria in Group A</p></caption><graphic xlink:href="AYU-35-152-g006"/></table-wrap><p>In group B, S. cholesterol, S. TGs, S. LDL, and S. VLDL were reduced by 6.31%, 9.61%, 12.55%, and 8.99% respectively, whereas S. HDL and apo-lipoprotein were increased by 10.52% and 1.89%. The results were statistically significant in S. cholesterol, S. LDL, S. HDL (<italic>P</italic> &#x0003c; 0.01) and insignificant in S. TGs, S. VLDL and apo-lipoprotein (<italic>P</italic> &#x0003e; 0.05) [<xref ref-type="table" rid="T3">Table 3</xref>].</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Effect of therapy on objective criteria in Group B</p></caption><graphic xlink:href="AYU-35-152-g007"/></table-wrap></sec><sec id="sec2-15"><title>Effect on bio-chemical parameters</title><p>In group A, 9.65% reduction was observed in FBS level, 5.15% decrease in S. creatinine, 0.97% increase in S. urea which is Within Normal Limit (WNL), although in group B 0.22% increase in FBS level (which is WNL), 1.0% decrease in S. creatinine, and 10.91% decrease in S. urea.</p></sec><sec id="sec2-16"><title>Comparison between both the groups</title><p>On comparison of both Groups, the un-paired <italic>t</italic> test showed insignificant difference in the objective parameters [<xref ref-type="table" rid="T4">Table 4</xref>]. While comparing the effect of therapy over the subjective criteria by using Chi-square analysis, both the groups showed similar effect as the results were insignificant [<xref ref-type="table" rid="T5">Table 5</xref>].</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Comparison between both the groups (subjective parameters)</p></caption><graphic xlink:href="AYU-35-152-g008"/></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Comparison between both the groups (objective parameters)</p></caption><graphic xlink:href="AYU-35-152-g009"/></table-wrap></sec><sec id="sec2-17"><title>Overall effect of therapy</title><p>In group A, 27 patients had completed the course of treatment. Out of them moderate improvement was observed in 4 (14.81%) patients, mild improvement was observed in 19 (70.37%) patients, whereas no improvement was observed in 4 (14.81%) patients.</p><p>In group B, 27 patients had completed the course of treatment; out of them moderate improvement was observed in 1 (3.70%) patient, mild improvement was observed in 20 (74.07%) patients, whereas no improvement was observed in 6 (22.22%) patients.</p></sec></sec><sec sec-type="discussion" id="sec1-5"><title>Discussion</title><p>The term <italic>Margavarana</italic> signifies the obstruction in the channels; in this study <italic>Margavarana</italic> refers to obstruction in <italic>Raktamarga</italic> rather than other channels within the body. S. cholesterol in patients of groups A and B were decreased by 7.12% and 6.31% respectively, which was statistically significant (<italic>P</italic> &#x0003c; 0.05). S. cholesterol is the total level of cholesterol that is found in the blood stream. Moreover, it helps to have a rough idea regarding the balance between the HDL and LDL cholesterol. Hence, the reduction in cholesterol levels that is significant has to be considered as a positive outcome of the trial drugs. On S. TG both drugs showed a decrease by 7.72% and 9.29% respectively, which was statistically insignificant. When absorption of triglyceride in the intestine is proper, it may reduce S. TG level. Over production of VLDL and triglyceride in the liver has been proposed to be driven by high levels of Serum free fatty acid in patients with insulin resistance.[<xref rid="ref6" ref-type="bibr">6</xref>] The ingredients of AG and GH are hepato-protective and anti-hypercholesterolemic. Hence, it can be understood that the action of drug is mainly on the endogenous/hepatic pathway of lipids. Both drugs showed S. VLDL decrease by 7.73% and 8.99% with a mean difference of 16.54 and 11.76 respectively, but it was statistically insignificant. VLDL contains the highest amount of TGs, and it is also considered as bad cholesterol as it helps cholesterol build up on walls of arteries. Hence, drop in the mean VLDL value attained in working groups is supporting the lipid lowering efficacy of AG and GH.</p><p>On S. LDL both drugs showed a decrease by 11.68% and 12.55% respectively, which was statistically significant. In the present study, mean cholesterol level was decreased, and mean HDL level was increased, which directly indicates the reduction of LDL level. The probable mechanism may be that the trial drugs reduce intestinal absorption of cholesterol by reducing the LDL particle concentrations. In AG; <italic>Asana</italic> (<italic>Pterocarpus marsupium</italic> Roxb.), <italic>Arjuna</italic> (<italic>Terminalia arjuna</italic> W. and A.), <italic>Shirisha</italic>, <italic>Rakta-Chandana</italic> (<italic>Pterocapus santalinus</italic> Linn.f.), <italic>Shaka</italic> (<italic>Tectona grandis</italic> Linn.); and in GH, both <italic>Gomutra</italic>[<xref rid="ref7" ref-type="bibr">7</xref>] and <italic>Haritaki</italic>[<xref rid="ref8" ref-type="bibr">8</xref>] may have anti-oxidant activity. Both drugs may reduce oxidative stress by preventing lipid peroxidation with more than two double bonds (free radicals). In both groups, S. HDL was increased by 9.52% and 10.52% respectively, which was statistically significant. HDL is considered as good cholesterol because of its effectiveness in cholesterol removal from the periphery to liver (reverse cholesterol transport). Drugs probably inhibit an enzyme in the liver that is involved in triglyceride synthesis, causing a decrease in VLDL production. It in turn leads to reduction in free fatty acids in the visceral fat levels, and thereby improvement in the HDL levels.</p><p>Apo-B 100 is the primary apo-lipoprotein of the LDL which is responsible for carrying cholesterol to the tissues. The normal level is considered as 40-125 mg/dl. In the present study, both groups showed an increase in Apo-B level but were within normal limits. In AG group, FBS was reduced by 9.55% although in GH group, FBS was increased by 0.22%, but it is within normal limit. Ingredients of AG such as <italic>Asana</italic>, <italic>Karanja</italic> (<italic>Pongamia glabra</italic> Vent), <italic>Khadira</italic> (<italic>Acacia catechu</italic> Willed), <italic>Mesha-sringi</italic> (<italic>Gymnema Sylvester</italic> R.Br), <italic>Daruharidra</italic> (<italic>Berberis aristata</italic> DC.), <italic>Shaka</italic>, and <italic>Kalinga</italic> are established hypoglycemic drugs. This study proves that, AG is an ideal drug which can lower the BSL (in pre-diabetics and diabetics).</p><p>AG and GH both showed improvement on <italic>Angagaurava</italic>, which was decreased by 85.36% and 90.08% respectively. <italic>Guru Guna</italic>, which is mainly responsible for <italic>Angagaurava</italic> is also a causative factor for increasing <italic>Ama</italic> resulting in formation of <italic>Pralepa</italic> in <italic>Rasavaha</italic> and <italic>Raktavaha Srotasa</italic>. <italic>Tikshna</italic>, <italic>Ushna</italic>, and <italic>Ruksha Guna</italic> of GH help to subside <italic>Gaurava</italic> by clearing <italic>Sroto-avarodha</italic>. AG showed improvement on <italic>Daurbalya</italic>, which was decreased by 81.81%, which is mainly due to <italic>Sroto-Avarodha</italic>, which ultimately hampers the nutrition of next <italic>Dhatu</italic>. AG decreases <italic>Kleda</italic> as well as <italic>Sroto-Avarodha</italic>. <italic>Atikshudha</italic> and <italic>Atipipasa</italic> are due to <italic>Tikshnata</italic> of <italic>Pachakagni</italic> and increased <italic>Vata</italic> in <italic>Koshtha Sthana</italic>.[<xref rid="ref9" ref-type="bibr">9</xref>] GH increase <italic>Jatharagni</italic> by <italic>Amapachana</italic>. It clears <italic>Sroto-avarodha</italic> and <italic>Medomargavarana</italic>. Ultimately, <italic>Prakruta Gati</italic> of <italic>Vata</italic> leads to <italic>Samyaka Kshudha</italic> and <italic>Pipasa</italic>. <italic>Sandhishoola</italic> is due to <italic>Bharavridhhi</italic> (<italic>Rasagata Sama Shleshma</italic>) or <italic>Samata</italic> (<italic>Medogata Sama Sleshma</italic>). <italic>Amapachana</italic> property of GH decreases <italic>Sandhishoola</italic> by converting <italic>Sama</italic> condition into <italic>Nirama</italic>. <italic>Tikta</italic>, <italic>Kashaya</italic>, <italic>Sheeta</italic>, <italic>Pitta-Kaphahara</italic> property of AG decrease <italic>Kleda</italic> and <italic>Meda</italic> as well as it reduces <italic>Swedadhikya</italic> and <italic>Daurgandhya</italic>. <italic>Alasya</italic> is due to Hetu like <italic>Guru</italic>, <italic>Snigdha</italic>, <italic>Madhura Ahara</italic>, which produce <italic>Ama</italic>, <italic>Kleda</italic>, <italic>Abhishyanda</italic>, <italic>Sroto-Avarodha</italic>. AG has <italic>Laghu</italic>, <italic>Ruksha</italic> and <italic>Tikta-Kashaya</italic> property. It helps in <italic>Kleda Upashoshana</italic>, decreases <italic>Abhishyanda</italic>, <italic>Sroto-Avarodha</italic> and <italic>Alasya</italic>. <italic>Ayase Swasa</italic> is one of the symptoms of <italic>Medo Vridhhi</italic>. Reduction in <italic>Apachita Medovriddhi</italic> (<italic>Medakshaya</italic>) showed improvement on the symptoms like <italic>Ayase Swasa</italic>. <italic>Nidradhikyata</italic> (<italic>Tamo Sleshma Samudbhava</italic>) is either due to <italic>Sroto-avarodha</italic> or <italic>Manasa Tamo Adhikya</italic> (<italic>Manovaha Srotasa</italic>).</p><sec id="sec2-18"><title>Probable mode of action of AG</title><p>Due to <italic>Kleda Dustikara Nidana</italic>, it increases <italic>Kleda</italic>, <italic>Sleshma</italic>, and <italic>Snehamsha</italic> in <italic>Rasa</italic>, <italic>Rakta</italic>, and <italic>Medo Dhatu</italic>. <italic>Guru</italic> and <italic>Snigdha Guna</italic> manifest symptoms such as <italic>Medovridhhi</italic>, <italic>Sphik-Stana-Udara Avalambana</italic>, <italic>Ayase Swasa</italic>, <italic>Daurbalya</italic>, <italic>Daurgandhya</italic>, <italic>Swedadhikya</italic> result in <italic>Kleda Bahula Samprapti Janya Vyadhi</italic> such as <italic>Prameha</italic>, <italic>Kustha</italic>, and <italic>Meda-roga</italic>. AG has <italic>Laghu</italic>, <italic>Ruksha</italic>, <italic>Sheeta</italic>, <italic>Tikta</italic>, <italic>Kashaya</italic>, and <italic>Katu Vipaka</italic>. <italic>Tikta</italic>, <italic>Kashaya</italic> and <italic>Sheeta</italic> having action of <italic>Kleda</italic>, <italic>Medo</italic>, <italic>Vasa</italic>, <italic>Mutra</italic>, <italic>Sweda Shoshana</italic>, <italic>Shodhana</italic> and <italic>Rakta Prasadana</italic>, which decrease <italic>Raktagata Kleda</italic> and <italic>Meda</italic>. Ultimately reduce <italic>Medoshaithilya</italic>. AG probably works at the level of <italic>Medodhatwagni</italic>. Ingredients of AG, <italic>Asana</italic>[<xref rid="ref10" ref-type="bibr">10</xref>] having action of anti-hyperlipidemic, anti-diabetic, cardiac tonic; <italic>Tinisha</italic> (<italic>Ougeinia dalbergioldes</italic> Benth.)[<xref rid="ref11" ref-type="bibr">11</xref>] having anti-inflammatory, cancer preventive, hypocholesterolemic; <italic>Arjuna</italic>[<xref rid="ref12" ref-type="bibr">12</xref>] having cardiotonic, antihyperlipidemic, antiatherogenic, antioxidant; <italic>Karanja</italic>[<xref rid="ref13" ref-type="bibr">13</xref>] having hypolipidemic, hypoglycemic action. It was observed that methanolic bark extract of <italic>Kadara</italic> (<italic>Acacia suma</italic> Kurz.)[<xref rid="ref14" ref-type="bibr">14</xref>] is potential to prevent the secondary complications of diabetes mellitus like atherosclerosis. <italic>Daruharidra</italic>[<xref rid="ref15" ref-type="bibr">15</xref>] has hypoglycemic, hypolipidemic, and anti-inflammatory activities; <italic>Dhava</italic> (<italic>Anogeissus latifolia</italic> Wall.)[<xref rid="ref16" ref-type="bibr">16</xref>] shows hypolipidemic and hepatoprotective activity, whereas <italic>Khadira</italic>[<xref rid="ref17" ref-type="bibr">17</xref>] is well-known of having anti-dyslipidemic and anti-diabetic property.</p><p>Anti-inflammatory drugs are potential enough for endothelial protection by reducing endothelial injury. Anti-oxidant drugs reduce chances of atherosclerotic complications like CVA (cerebrovascular accident), whereas hypoglycemic drugs improve carbohydrate metabolism and glycogenesis by reducing excess lipogenesis. Hepatoprotective drugs enhance the enzyme useful for HDL production. Over all AG is cardioprotective and hepatoprotective. Ultimately, it is useful to regulate lipid metabolism</p></sec><sec id="sec2-19"><title>Probable mode of action of GH</title><p>Due to <italic>Dustikara Nidana</italic>, it increases <italic>Sama Sleshma</italic>, <italic>Agnimandhya</italic> and <italic>Amarasa</italic>. <italic>Rasagata Ama</italic> manifests symptoms such as <italic>Apachita Medo Dhatu Vridhhi</italic>, <italic>Bharavridhhi</italic>, <italic>Angagaurava</italic>, <italic>Sroto-avarodha</italic>. And <italic>Sama Sleshma</italic> causes symptoms such as <italic>Angagaurava</italic>, <italic>Sroto-avarodha</italic>, <italic>Ati Kshudha</italic>, <italic>Ati Pipasa</italic>, and <italic>Asthi-Sandhishoola</italic>. It may lead to <italic>Ama Bahula Samprapti Janya Vyadhi</italic> such as <italic>Medoroga</italic>, <italic>Madhyama Margavaranajanya Vyadhi</italic>, <italic>Trimarmiya Vyadhi</italic>. <italic>Gomutra</italic> (of GH) possesses <italic>Katu Rasa</italic> and <italic>Ushna Virya</italic>, whereas <italic>Haritaki</italic> has property of <italic>Doshanuloman</italic>, <italic>Dipana-pachana</italic>, <italic>Sroto Vibandhanahara</italic>, <italic>Pramehahara</italic>, <italic>Hridaya-urah Pralepahara</italic>, and <italic>Budhhi Indriya Bala Prada</italic>. GH increases <italic>Jatharagni</italic> by <italic>Amapachana</italic> reducing <italic>Sama Sleshma</italic> and <italic>Apachita Medo Dhatu</italic>. GH probably works at the level of <italic>Jatharagni</italic>.</p><p>Triglyceride and other cholesterol are usually absorbed in gastro-intestinal tract (GIT). When <italic>Jatharagni Vikriti</italic> occurs, it manifests in <italic>Ama</italic>, disturbs lipid metabolism, increases triglyceride and other cholesterol. GH improves physiological digestion process at the level of the intestine and liver. It also regulates lipid metabolism. <italic>Gomutra</italic>[<xref rid="ref18" ref-type="bibr">18</xref>] (bio-enhancer) can enhance the efficacy and effect of other drugs. <italic>Haritaki</italic>[<xref rid="ref19" ref-type="bibr">19</xref>] has anti-hyperlipidemic, anti-oxidant, cytoprotective, anti-diabetic, cardioprotective as well as hepatoprotective activity. Over all, GH is cardioprotective and hepatoprotective, and it promotes physiological digestive process.</p></sec></sec><sec sec-type="conclusion" id="sec1-6"><title>Conclusion</title><p>On comparison, both drugs <italic>Asanadi Ghanavati</italic> and <italic>Gomutra Haritaki</italic> showed better result on dyslipidemia. <italic>Asanadi Ghanavati</italic> is more useful in pre-diabetic and diabetic, dyslipidemic patients while <italic>Gomutra Haritaki</italic> has an additional advantage of improving physiological digestive process. <italic>Asanadi Ghanavati</italic> probably works at the level of <italic>Medodhatwagni</italic>. <italic>Gomutra Haritaki</italic> probably works at the level of <italic>Jatharagni</italic>. <italic>Asanadi Ghanavati</italic> and <italic>Gomutra Haritaki</italic> should be used in <italic>Kleda Bahul Samprapti Janya Vyadhi</italic> and <italic>Ama Bahul Samprapti Janya Vyadhi</italic> respectively. The ingredients of <italic>Gomutra Haritaki</italic> are cost-effective and easily available throughout the country. Finally, <italic>Gomutra Haritaki</italic> is a potent drug in the management of dyslipidemia both as a prophylactic and curative agent.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Indrayan</surname><given-names>A</given-names></name></person-group><article-title>Forecasting vascular disease cases and associated mortality in India. Reports of the National Commission on Macroeconomics and Health</article-title><year>2005</year><date-in-citation>Last accessed on 2012 Mar 20</date-in-citation><publisher-loc>India</publisher-loc><publisher-name>Ministry of Health and FamilyWelfare</publisher-name><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.whoindia.org/EN/Section102/Section201_888.htm">http://www.whoindia.org/EN/Section102/Section201_888.htm</uri></comment></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="webpage"><article-title>Global status report non-communicable disease</article-title><year>2010</year><date-in-citation>Last accessed on 2012 Sep 10</date-in-citation><comment>Available from: <uri xlink:type="simple" xlink:href="http://www.who.int/nmh/publications/ncd_report_full_en.pdf">http://www.who.int/nmh/publications/ ncd_report_full_en.pdf</uri></comment></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vagbhata</surname></name><name><surname>Ashtanga</surname><given-names>Hridaya</given-names></name><name><surname>Sutra</surname><given-names>Sthana</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bramhananda</surname><given-names>Tripathi</given-names></name></person-group><article-title>Shodhanadi Adhyaya, 15/19-20</article-title><year>2007</year><edition>reprint ed</edition><publisher-loc>Delhi</publisher-loc><publisher-name>Chaukhambha Sanskrit Pratishthan</publisher-name><fpage>199</fpage><lpage>200</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Agnivesha</surname></name><name><surname>Charaka</surname></name><name><surname>Dridhabala</surname></name><name><surname>Charaka</surname><given-names>Samhita</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bramhananda</surname><given-names>Tripathi</given-names></name></person-group><article-title>Chikitsa Sthana, Shwayathuchikitsa Adhyaya, 12/21</article-title><year>2008</year><volume>2</volume><edition>reprint ed</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Chukhambha Surbharati</publisher-name><fpage>443</fpage></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name><name><surname>Hauser</surname><given-names>SL</given-names></name><name><surname>Longo</surname><given-names>DL</given-names></name><name><surname>Jameson</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Harrison's Principles of Internal Medicine</article-title><year>2007</year><volume>2</volume><edition>17th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw Hill Publications</publisher-name><comment>Appendix</comment></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>LA</given-names></name><name><surname>B&#x000f6;ttiger</surname><given-names>LE</given-names></name></person-group><article-title>Ischaemic heart-disease in relation to fasting values of plasma triglycerides and cholesterol. Stockholm prospective study</article-title><source>Lancet</source><year>1972</year><volume>1</volume><fpage>865</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">4111826</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwin</surname><given-names>J</given-names></name><name><surname>Edwin</surname><given-names>S</given-names></name><name><surname>Tiwari</surname><given-names>V</given-names></name><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Toppo</surname><given-names>E</given-names></name></person-group><article-title>Antioxidant and antimicrobial activities of cow urine</article-title><source>Glob J Pharmacol</source><year>2008</year><volume>2</volume><fpage>20</fpage><lpage>22</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Won</surname><given-names>NH</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Jun</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>KW</given-names></name></person-group><article-title>Antioxidant effects of aqueous extract of <italic>Terminalia chebula</italic>
<italic>in vivo</italic> and <italic>in vitro</italic></article-title><source>Biol Pharm Bull</source><year>2005</year><volume>28</volume><fpage>1639</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16141531</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Charaka</surname></name><name><surname>Dridhabala</surname></name><name><surname>Charaka</surname><given-names>Samhita</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bramhananda</surname><given-names>Tripathi</given-names></name></person-group><article-title>Sutra Sthana, Ashtoninditiya Adhyaya, 21/04</article-title><year>2008</year><volume>1</volume><edition>reprint ed</edition><publisher-loc>Varanasi</publisher-loc><publisher-name>Chukhambha Surbharati</publisher-name><fpage>399</fpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maruthupandian</surname><given-names>A</given-names></name><name><surname>Mohan</surname><given-names>VR</given-names></name></person-group><article-title>GC-MS analysis of some bioactive constituents of <italic>Pterocarpus marsupium</italic> Roxb</article-title><source>International Journal of ChemTech Research</source><year>2011</year><volume>3</volume><fpage>1652</fpage><lpage>57</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velmurugan</surname><given-names>C</given-names></name><name><surname>Sundaram</surname><given-names>T</given-names></name><name><surname>Sampath</surname><given-names>Kumar R</given-names></name><name><surname>Vivek</surname><given-names>B</given-names></name><name><surname>Sheshadrishekar</surname><given-names>D</given-names></name><name><surname>Ashok Kumar</surname><given-names>BS</given-names></name></person-group><article-title>Anti-diabetic and hypolipidemic activity of bark of ethanolic extract of <italic>ougeinia oojeinensis</italic> (ROXB)</article-title><source>Med J Malaysia</source><year>2011</year><volume>66</volume><fpage>22</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">23765138</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name><name><surname>Uthrapathi</surname><given-names>S</given-names></name><name><surname>Gnamanickam</surname><given-names>VR</given-names></name><name><surname>Dubey</surname><given-names>GP</given-names></name></person-group><article-title>Anti-hyperlipidemic and antioxidant potential of different fraction of <italic>Terminalia arjuna</italic> Roxb. bark against PX-407 induced hyperlipidemia</article-title><source>Indian J Exp Biol</source><year>2011</year><volume>49</volume><fpage>282</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21614892</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Semalty</surname><given-names>A</given-names></name><name><surname>Mir</surname><given-names>SR</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Amin</surname><given-names>S</given-names></name></person-group><article-title>Hypoglycemic and hypolipidemic activity of <italic>Pongamia pinnata</italic> (Linn.) pierre in streptozotocin-induced diabetic rats</article-title><source>Int J Pharmacol</source><year>2010</year><volume>6</volume><fpage>738</fpage><lpage>743</lpage></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acharyya</surname><given-names>S</given-names></name><name><surname>Dash</surname><given-names>GK</given-names></name><name><surname>Pattnaik</surname><given-names>S</given-names></name><name><surname>Chhetree</surname><given-names>RR</given-names></name></person-group><article-title>Antihyperglycemic and antihyperlipidemic activity of <italic>Acacia suma</italic> (Roxb.) barks</article-title><source>Res J Pharmacol Pharmacodyn</source><year>2011</year><volume>03</volume><fpage>67</fpage><lpage>71</lpage></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzaq</surname><given-names>FA</given-names></name><name><surname>Khan</surname><given-names>RA</given-names></name><name><surname>Feroz</surname><given-names>Z</given-names></name><name><surname>Afroz</surname><given-names>S</given-names></name></person-group><article-title>Effect of <italic>Berberis aristata</italic> on lipid profile and coagulation parameters</article-title><source>Afr J Pharm Pharmacol</source><year>2011</year><volume>5</volume><fpage>943</fpage><lpage>7</lpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>UH</given-names></name><name><surname>Gaikwad</surname><given-names>DK</given-names></name></person-group><article-title>Ethno-pharmacological review of a herbal drug: <italic>Anogeissus latifolia</italic></article-title><source>Int J Pharma Sci Res</source><year>2011</year><volume>2</volume><fpage>41</fpage><lpage>3</lpage></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Bhatia</surname><given-names>V</given-names></name></person-group><article-title><italic>Acacia catechu</italic> hard wood: Potential anti-diabetic cum anti-dyslipidemic</article-title><source>Med Chem Res</source><year>2011</year><volume>20</volume><fpage>1732</fpage><lpage>9</lpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randhawa</surname><given-names>GK</given-names></name></person-group><article-title>Cow urine distillate as bioenhancer</article-title><source>J Ayurveda Integr Med</source><year>2010</year><volume>1</volume><fpage>240</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">21731367</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>AK</given-names></name><name><surname>Bansal</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name></person-group><article-title>Phytochemistry and pharmacological activities of Haritaki- A review</article-title><source>Journal of pharmacy research</source><year>2010</year><volume>3</volume><fpage>417</fpage><lpage>24</lpage></element-citation></ref></ref-list></back></article>